Literature DB >> 9737460

In vivo analysis of antithrombotic effectiveness of recombinant hirudin on microvascular thrombus formation and recanalization.

F Roesken1, B Vollmar, M Rücker, D Seiffge, M D Menger.   

Abstract

PURPOSE: This study was undertaken to evaluate in vivo the effect of recombinant hirudin (r-hirudin [HBW 023]), a potent thrombin inhibitor, on the process of microvascular thrombus formation and recanalization.
METHODS: Thrombosis was induced photochemically in distinct arterioles (n = 25) and venules (n = 30) of the ear of 16 hairless hr/hr mice (8 to 10 weeks old, 25 to 30 g of body weight). r-Hirudin (1 mg/kg of body weight) was administered intravenously directly before thrombus induction; saline-treated animals served as controls. Thrombus formation (i.e., first platelet deposition at the endothelial lining [FPD]; inner luminal diameter reduction to 50% [D/2]; complete vessel occlusion [CVO]), vessel recanalization, microcirculatory parameters, and leukocyte-endothelial cell interaction were analyzed by means of intravital fluorescence microscopy.
RESULTS: Hirudin significantly delayed the process of thrombus formation compared with saline-treated controls in both arterioles (FPD: 381 +/- 80 vs 137 +/- 25 seconds, P < 0.05; D/2: 627 +/- 49 vs 501 +/- 71 seconds; CVO: 925 +/- 78 vs 854 +/- 60 seconds) and venules (FPD: 173 +/- 11 vs 59 +/- 4 seconds; D/2: 342 +/- 54 vs 228 +/- 27 seconds; CVO: 541 +/- 85 vs 344 +/- 43 seconds; P < 0.05). In addition, r-hirudin-treated animals showed an increased rate of vessel recanalization at 24 hours after thrombus induction (arterioles: 54% [7 of 13] vs 0% [0 of 12], P < 0.05; venules: 77% [10 of 13] vs 53% [9 of 17]), whereas microcirculatory parameters and leukocyte-endothelial cell interaction were not affected.
CONCLUSION: Our data indicate that r-hirudin not only counteracts the process of thrombus formation but also promotes vessel recanalization, thus supporting its use in clinical microvascular surgery.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9737460     DOI: 10.1016/s0741-5214(98)70136-3

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  5 in total

Review 1.  Thrombus formation in vivo.

Authors:  Bruce Furie; Barbara C Furie
Journal:  J Clin Invest       Date:  2005-12       Impact factor: 14.808

2.  Laser-induced noninvasive vascular injury models in mice generate platelet- and coagulation-dependent thrombi.

Authors:  E D Rosen; S Raymond; A Zollman; F Noria; M Sandoval-Cooper; A Shulman; J L Merz; F J Castellino
Journal:  Am J Pathol       Date:  2001-05       Impact factor: 4.307

3.  Experimental models to study microcirculatory dysfunction in muscle ischemia-reperfusion and osteomyocutaneous flap transfer.

Authors:  Michael D Menger; Matthias W Laschke; Michaela Amon; Rene Schramm; Henrik Thorlacius; Martin Rücker; Brigitte Vollmar
Journal:  Langenbecks Arch Surg       Date:  2003-10-07       Impact factor: 3.445

Review 4.  Antiviral anticoagulation.

Authors:  Edward L G Pryzdial; Michael R Sutherland; Bryan H Lin; Marc Horwitz
Journal:  Res Pract Thromb Haemost       Date:  2020-07-06

5.  A novel hirudin derivative characterized with anti-platelet aggregations and thrombin inhibition.

Authors:  Wei Mo; Yan-Ling Zhang; Hong-Shan Chen; Long-Sheng Wang; Hou-Yan Song
Journal:  J Thromb Thrombolysis       Date:  2008-11-09       Impact factor: 2.300

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.